XCUR Stock Price, Exicure Inc Quote, Chart

Market Summary

USD0.50-0.02

Market Closed

-3.85%

XCUR Stock Price

View Fullscreen

XCUR RSI Chart

XCUR Valuation

Market Cap

4.3M

Price/Earnings (Trailing)

1.52

Price/Sales (Trailing)

0.16

EV/EBITDA

0.58

Price/Free Cashflow

-0.27

XCUR Price/Sales (Trailing)

XCUR Profitability

EBT Margin

11.02%

Return on Equity

66.01%

Return on Assets

22.93%

Free Cashflow Yield

-373.83%

XCUR Fundamentals

XCUR Revenue

Revenue (TTM)

28.8M

XCUR Earnings

Earnings (TTM)

3.0M

Earnings Growth (Yr)

-1.86%

Earnings Growth (Qtr)

8.81%

Breaking Down XCUR Revenue

Last 7 days

8.7%

Last 30 days

-16.7%

Last 90 days

-16.7%

Trailing 12 Months

-49.0%

How does XCUR drawdown profile look like?

XCUR Financial Health

Current Ratio

1.39

XCUR Investor Care

Shares Dilution (1Y)

3.34%

Diluted EPS (TTM)

2.17

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	0	0	0	0
2022	3.8M	6.1M	7.1M	28.8M
2021	8.4M	3.7M	0	0
2020	10.5M	14.9M	16.8M	16.6M
2019	107.0K	522.0K	992.0K	1.3M
2018	7.3M	4.9M	2.5M	118.0K
2017	3.2M	5.4M	7.5M	9.7M
2016	0	0	1.7M	1.0M
2015	0	0	0	2.4M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Exicure Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Feb 29, 2024	dgp co., ltd.	sold	-4,488,000	1.32	-3,400,000	-
Feb 16, 2024	miller josh	sold (taxes)	-27.4988	0.5978	-46.00	chief accounting officer
Nov 16, 2023	miller josh	sold (taxes)	-21.47	0.565	-38.00	chief accounting officer
Aug 16, 2023	miller josh	sold (taxes)	-30.71	0.83	-37.00	chief accounting officer
Jun 23, 2023	cbi usa, inc.	sold	-5,440,000	1.6	-3,400,000	-
May 16, 2023	miller josh	sold (taxes)	-198	1.0728	-185	chief accounting officer
Dec 15, 2022	cbi usa, inc.	bought	5,440,000	1.6	3,400,000	-
May 19, 2022	muralidhar bali	bought	285,152	0.1937	1,472,130	-
Dec 21, 2021	gates frontier, llc	sold	-303,200	0.239	-1,268,620	-
Nov 15, 2021	feltner douglas e.	acquired	6,825	0.91	7,500	chief medical officer

Which funds bought or sold XCUR recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	Tower Research Capital LLC (TRC)	added	0.85	189	4,233	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	new	-	7,693	7,693	-%
May 15, 2024	MORGAN STANLEY	reduced	-5.66	-42.00	1,856	-%
May 15, 2024	CITADEL ADVISORS LLC	new	-	10,923	10,923	-%
May 15, 2024	TWO SIGMA SECURITIES, LLC	added	35.7	3,947	13,653	-%
May 15, 2024	Royal Bank of Canada	added	32.26	-	-	-%
May 15, 2024	MILLENNIUM MANAGEMENT LLC	reduced	-39.81	-13,236	20,933	-%
May 14, 2024	Farther Finance Advisors, LLC	new	-	28.00	28.00	-%
May 14, 2024	LAZARD ASSET MANAGEMENT LLC	new	-	-	-	-%
May 13, 2024	UBS Group AG	added	7.26	113	1,103	-%

Are Funds Buying or Selling XCUR?

Are funds buying XCUR calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own XCUR

No. of Funds

Unveiling Exicure Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 04, 2024	cbi usa, inc.	9.5%	818,299	SC 13D/A
Aug 08, 2023	cbi usa, inc.	9.5%	818,299	SC 13D/A
Jun 28, 2023	cbi usa, inc.	9.8%	818,299	SC 13D/A
May 17, 2023	cbi usa, inc.	50.4%	4,218,299	SC 13D/A
May 01, 2023	cbi usa, inc.	50.4%	4,218,299	SC 13D/A
Apr 13, 2023	carlyle group inc.	3.4%	287,137	SC 13D/A
Mar 03, 2023	cbi usa, inc.	50.4%	4,218,299	SC 13D/A
Feb 14, 2023	armistice capital, llc	4.99%	260,746	SC 13G/A
Feb 13, 2023	cbi usa, inc.	50.4%	4,218,299	SC 13D/A
Feb 09, 2023	carlson capital l p	4.3%	212,283	SC 13G/A

Recent SEC filings of Exicure Inc

View All Filings

Date Filed	Form Type	Document
May 16, 2024	8-K	Current Report
May 16, 2024	10-Q/A	Quarterly Report
May 16, 2024	10-Q/A	Quarterly Report
May 16, 2024	10-Q	Quarterly Report
May 15, 2024	NT 10-Q	NT 10-Q
Apr 22, 2024	8-K	Current Report
Apr 01, 2024	NT 10-K	NT 10-K
Mar 06, 2024	4	Insider Trading
Mar 04, 2024	SC 13D/A	13D - Major Acquisition
Mar 04, 2024	4	Insider Trading

Peers (Alternatives to Exicure Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.91	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.68	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.3	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.27	14.48	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	234.45%	75.34%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Exicure Inc News

Latest updates

Exicure Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2	2018Q1
Revenue	-	-	-	-	21,774,000	2,016,000	2,471,000	2,565,000	79,000	997,000	140,000	2,443,000	4,847,000	9,183,000	310,000	527,000	434,000	25,000	6,000	57,000	19,000	1,057,000
Operating Expenses	-41.2%	3,317,000	5,642,000	4,539,000	3,180,000	7,221,000	9,954,000	10,302,000	13,941,000	13,154,000	12,600,000	11,563,000	9,237,000	8,649,000	10,419,000	6,473,000	5,418,000	5,603,000	4,874,000	5,920,000	5,823,000	5,320,000
S&GA Expenses	-100.0%	-	4,721,000	2,558,000	2,107,000	2,416,000	3,205,000	3,162,000	3,098,000	2,892,000	2,728,000	2,424,000	2,229,000	2,574,000	2,152,000	2,228,000	1,985,000	2,208,000	1,866,000	1,919,000	1,988,000	2,045,000
R&D Expenses	-100.0%	-	921,000	1,981,000	1,073,000	4,805,000	6,749,000	7,140,000	10,843,000	10,262,000	9,872,000	9,139,000	7,008,000	6,075,000	8,267,000	4,245,000	3,433,000	3,395,000	3,008,000	4,001,000	3,835,000	3,275,000
EBITDA Margin	-5.5%	0.14	0.15	0.09	-0.02	-4.58	-8.28	-15.06	-6.12	-2.72	-1.40	-1.51	-	-	-	-	-	-	-	-	-	-
Interest Expenses	-	-	-	-	-	-	-	595,000	450,000	409,000	418,000	27,000	-	128,000	197,000	203,000	203,000	183,000	175,000	170,000	166,000	161,000
Income Taxes	-	-	-	-	209,000	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Earnings Before Taxes	8.8%	-5,256,000	-5,764,000	-4,407,000	18,605,000	-5,160,000	-7,470,000	-8,348,000	-14,269,000	-12,477,000	-	-	-	-	-	-	-	-	-	-	-	-
EBT Margin	-2.9%	0.11	0.11	0.05	-0.08	-4.88	-8.70	-15.86	-6.74	-2.93	-1.48	-1.57	-	-	-	-	-	-	-	-	-	-
Net Income	8.8%	-5,256,000	-5,764,000	-4,407,000	18,396,000	-5,160,000	-7,470,000	-8,348,000	-14,269,000	-12,477,000	-12,685,000	-8,822,000	-4,311,000	1,150,000	-9,981,000	-5,816,000	-5,220,000	-5,286,000	-4,755,000	-5,324,000	-6,825,000	-5,509,000
Net Income Margin	-3.1%	0.10	0.11	0.05	-0.09	-4.88	-8.70	-15.86	-13.19	-4.54	-1.48	-1.31	-	-	-	-	-	-	-	-	-	-
Free Cashflow	70.7%	-1,412,000	-4,811,000	-3,318,000	-7,276,000	-6,548,000	-9,082,000	-12,762,000	-11,415,000	-15,034,000	-11,904,000	-8,727,000	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3
Assets	-26.2%	13.00	18.00	24.00	23.00	29.00	37.00	42.00	65.00	78.00	74.00	88.00	100	111	96.00	106	115	74.00	20.00	25.00	29.00	36.00
Current Assets	-15.7%	3.00	4.00	11.00	10.00	17.00	25.00	29.00	44.00	64.00	61.00	74.00	86.00	97.00	89.00	102	113	72.00	19.00	24.00	28.00	34.00
Cash Equivalents	-9.1%	2.00	2.00	10.00	9.00	16.00	22.00	25.00	44.00	53.00	44.00	35.00	34.00	33.00	18.00	26.00	48.00	70.00	17.00	22.00	26.00	32.00
Net PPE	-96.6%	0.00	2.00	2.00	3.00	3.00	3.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	2.00	2.00	2.00	1.00	1.00	1.00	1.00
Liabilities	7.7%	8.00	8.00	9.00	8.00	33.00	36.00	39.00	54.00	64.00	38.00	38.00	39.00	38.00	14.00	20.00	35.00	9.00	9.00	9.00	8.00	10.00
Current Liabilities	55.2%	2.00	1.00	3.00	2.00	26.00	20.00	21.00	34.00	22.00	13.00	13.00	14.00	13.00	14.00	20.00	31.00	8.00	8.00	8.00	2.00	9.00
Long Term Debt	-	-	-	-	-	-	-	-	-	17.00	17.00	17.00	17.00	17.00	-	-	-	-	-	-	5.00	-
LT Debt, Current	-	-	-	-	-	-	-	-	7.00	-	-	-	-	-	-	-	5.00	5.00	5.00	5.00	-	5.00
LT Debt, Non Current	-	-	-	-	-	-	-	-	-	17.00	17.00	17.00	17.00	17.00	-	-	-	-	-	-	5.00	-
Shareholder's Equity	-53.7%	4.00	10.00	15.00	15.00	-3.70	1.00	3.00	11.00	14.00	37.00	50.00	62.00	73.00	82.00	85.00	81.00	65.00	11.00	16.00	21.00	25.00
Retained Earnings	-2.9%	-188	-182	-177	-172	-191	-185	-178	-170	-156	-132	-118	-105	-93.28	-84.46	-80.15	-81.30	-71.32	-65.50	-60.28	-54.99	-50.24
Additional Paid-In Capital	0.0%	193	193	192	188	187	187	182	181	170	169	168	167	166	166	165	162	136	77.00	76.00	76.00	75.00
Shares Outstanding	0.0%	9.00	9.00	8.00	5.00	5.00	5.00	4.00	4.00	3.00	3.00	3.00	3.00	3.00	-	-	-	-	-	-	-	-
Float	-	-	-	-	-	-	9.00	-	-	-	115	-	-	-	128	-	-	-	72.00	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3
Cashflow From Operations	70.7%	-1,412	-4,811	-3,318	-7,276	-6,548	-9,078	-12,756	-13,797	4,863	-11,076	-14,809	-11,807	-8,649	-10,967	-7,847	15,330	-5,017	-4,984	-4,012	-5,963	-4,193
Share Based Compensation	-94.8%	50.00	969	308	228	292	507	342	769	889	764	517	581	618	544	441	401	511	439	489	509	516
Cashflow From Investing	100.0%	-	-1,895	106	207	998	1,496	1,995	4,108	4,444	19,236	15,297	13,472	5,635	3,538	-12,503	-62,970	-400	-54.00	-8.00	-29.00	-5.00
Cashflow From Financing	99.9%	-1.00	-919	4,595	-	-2.00	4,890	-7,993	448	-9.00	131	546	138	17,275	50.00	-2,333	25,708	58,634	17.00	-52.00	-186	20,264

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

XCUR Income Statement

2023-03-31

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Revenue:
Collaboration revenue	$ 0	$ 2,565,000
Total revenue	0	2,565,000
Operating expenses:
Research and development expense	1,423,000	7,140,000
General and administrative expense	3,116,000	3,162,000
Total operating expenses	4,539,000	10,302,000
Operating loss	(4,539,000)	(7,737,000)
Other income (expense), net:
Dividend income	17,000	2,000
Interest income	11,000	2,000
Interest expense	0	(595,000)
Other income (expense), net	104,000	(20,000)
Total other income (expense), net	132,000	(611,000)
Net loss before provision for income taxes	(4,407,000)	(8,348,000)
Provision for income taxes	0	0
Net loss	$ (4,407,000)	$ (8,348,000)
Basic loss per common share (in dollars per share)	$ (0.70)	$ (2.07)
Diluted loss per common share (in dollars per share)	$ (0.70)	$ (2.07)
Weighted-average basic common shares outstanding (in shares)	6,288,952	4,031,316
Weighted-average diluted common shares outstanding (in shares)	6,288,952	4,031,316

XCUR Balance Sheet

2023-03-31

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 9,960	$ 8,577
Prepaid expenses and other assets	1,317	1,474
Total current assets	11,277	10,051
Property and equipment, net	2,279	2,530
Right-of-use asset	7,077	7,257
Other noncurrent assets	3,310	3,490
Total assets	23,943	23,328
Current liabilities:
Accounts payable	452	361
Accrued expenses and other current liabilities	1,477	1,278
Common stock warrant liability	800	0
Total current liabilities	2,729	1,639
Lease liability, noncurrent	6,595	6,767
Total liabilities	9,324	8,406
Stockholders’ equity:
Preferred stock, $0.0001 par value per share; 10,000,000 shares authorized, no shares issued and outstanding, March 31, 2023 and December 31, 2022	0	0
Common stock, $0.0001 par value per share; 200,000,000 shares authorized, 8,371,462 issued and outstanding, March 31, 2023; 4,965,901 issued and outstanding, December 31, 2022	1	0
Additional paid-in capital	191,674	187,571
Accumulated deficit	(177,056)	(172,649)
Total stockholders’ equity	14,619	14,922
Total liabilities and stockholders’ equity	$ 23,943	$ 23,328

About Exicure Inc

Exicure, Inc., an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.

CEO	Mr. Paul Kang
WEBSITE	exicuretx.com
INDUSTRY	Biotechnology
EMPLOYEES	7

Exicure Inc Frequently Asked Questions

What is the ticker symbol for Exicure Inc? What does XCUR stand for in stocks?

XCUR is the stock ticker symbol of Exicure Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Exicure Inc (XCUR)?

As of Fri May 17 2024, market cap of Exicure Inc is 4.33 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of XCUR stock?

You can check XCUR's fair value in chart for subscribers.

What is the fair value of XCUR stock?

You can check XCUR's fair value in chart for subscribers. The fair value of Exicure Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Exicure Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for XCUR so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Exicure Inc a good stock to buy?

The fair value guage provides a quick view whether XCUR is over valued or under valued. Whether Exicure Inc is cheap or expensive depends on the assumptions which impact Exicure Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for XCUR.

What is Exicure Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, XCUR's PE ratio (Price to Earnings) is 1.52 and Price to Sales (PS) ratio is 0.16. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. XCUR PE ratio will change depending on the future growth rate expectations of investors.